Fluorescent-labeled IgG for Liver Tumor Detection

• Status: Recruiting
• Trial end date: 2025-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma).

The main purposes of this study include:

• To validate the safety and effectiveness of using FluoAB in hepatic surgery.

• To raise the surgical precision with guidance by FluoAB fluorescence imaging.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Sciences

Criteria

Inclusion Criteria:

1. Patients who have been diagnosed with liver tumor.

2. Planned to receive hepatectomy.

3. Liver function Child-Pugh A/B.

4. The expected lifetime is longer than 6 months.

5. Approved to sign the informed consent.

Exclusion Criteria:

1. Enrolled in other trials in the past 3 months.

2. Metastatic lesions were found.

3. Undesirable function of heart, lung, kidney, or any other organs.

4. Unable to tolerate a hepatectomy.

5. The researchers considered inappropriate to be included.